CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0004-000 |
|---|---|
| Brand Name | Sutent |
| Generic Name | Sunitinib malate |
| Strength | 12.5mg, 25mg, 50mg |
| Tumour Type | Gastrointestinal |
| Indication | Pancreatic neuroendocrine tumours |
| Funding Request | Patients with unresectable locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumours, whose disease is progressive |
| Review Status | Complete |
| Pre Noc Submission | No |
| NOC Date | June 30, 2011 |
| Manufacturer | Pfizer Canada Inc. |
| Sponsor | Pfizer Canada Inc. |
| Submission Date | November 7, 2011 |
| Submission Deemed Complete | November 14, 2011 |
| Submission Type | Initial |
| Prioritization Requested | Not Requested |
| Stakeholder Input Deadline ‡ | November 22, 2011 |
| Check-point meeting | January 9, 2012 |
| pERC Meeting | February 16, 2012 |
| Initial Recommendation Issued | March 2, 2012 |
| Feedback Deadline ‡ | March 16, 2012 |
| pERC Reconsideration Meeting | April 19, 2012 |
| Final Recommendation Issued | May 3, 2012 |
| Notification to Implement Issued | May 18, 2012 |
| Therapeutic Area | Pancreatic Neuroendocrine Tumour |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
